On the contrary, our proposed approach resulted in rapid regression of severe OHSS as early as two days after initiation of GnRH antagonist, without any use of invasive treatment for the patients and avoiding the need for hospitalization. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.